HerAnova™ Named Femtech Company of the Year at the Health Tech World Awards 2026

Recognition highlights commitment to addressing unmet needs in endometriosis and women's health through HerResolve™, its non-invasive diagnostic innovation

BOSTON, MA, UNITED STATES, November 4, 2026 /EINPresswire.com/ -- HerAnova™ Lifesciences, a leading life sciences company dedicated to advancing innovative solutions for endometriosis, infertility and other critical unmet needs in women's health, today announced that it has been named Femtech Company of the Year at the Health Tech World Awards 2026.

The award, sponsored by Cross-Border Impact Ventures, recognizes a company advancing

women's health through innovative technology, with a focus on addressing unmet healthcare needs and making a meaningful difference for women. Health Tech World announced the winners at a ceremony on October 28, 2026.

"For women facing years of unexplained symptoms, the search for answers can take a profound physical and emotional toll," said Farideh Bischoff, PhD, Chief Medical Officer - Head of Diagnostics at HerAnova Lifesciences, who accepted the award on behalf of the Company. "We are honored to receive this recognition of our work to give clinicians better tools to help these women move forward. It reflects the dedication of our team and collaborators to bringing scientific innovation into clinical care, with patients' needs at the center."

HerAnova's work in endometriosis diagnostics centers on HerResolve™, its blood-based rule-in test designed to aid in the diagnosis of endometriosis in symptomatic women. In a clinical validation study published in the Journal of Minimally Invasive Gynecology, HerResolve™ demonstrated an AUC of 94%, 80% sensitivity, and 97.5% specificity.

Penny Wan, Co-Founder and Chairwoman of HerAnova, shares a powerful message for patients: "It's not you, it's endometriosis." With HerResolve™, patients and their doctors can gain the diagnostic clarity they need to take the next step toward managing the condition.

Read the official winners announcement from Health Tech World.

About HerResolve™

HerResolve™ is a multi-omic, blood-based diagnostic assay developed by HerAnova Lifesciences to aid in the diagnosis of endometriosis in symptomatic women of reproductive age. The test integrates microRNA, protein, and a hormone biomarker analyzed through a proprietary machine learning framework. HerResolve™ is the first and only commercially available non-invasive blood test developed to detect endometriosis, currently accessible at select IVF and reproductive medicine centers across the United States.

Endometriosis affects approximately 1 in 10 women of reproductive age, yet diagnosis often takes seven to ten years, largely because the current gold standard requires invasive laparoscopic surgery. HerResolve™ was developed to complement existing clinical pathways as a non-invasive triage tool, helping to identify patients who may benefit from further diagnostic evaluation or empirical treatment, reserving surgery for treatment rather than diagnosis of endometriosis.

About HerAnova Lifesciences

HerAnova Lifesciences Inc. is a leading life sciences company dedicated to advancing innovative solutions for endometriosis, infertility and other critical unmet needs in women's health. By integrating diagnostics, therapeutics, medical devices, and data analytics, HerAnova aims to provide a one-stop solution for unmet needs in obstetrics and gynecology. Founded in March 2022 in Boston by experienced entrepreneurs and former multinational executives, HerAnova operates globally on its research, development, and commercialization initiatives. For more information, visit https://heranova.com/.